Melanotan II (MT-II)

1. Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 and a molecular weight of 1024.2 Da [1][4]. It was developed in the late 1980s at the University of Arizona by Victor Hruby and Mac Hadley as a potential sunless tanning agent and skin cancer chemopreventive [1][5]. MT-II is a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, which accounts for its diverse pharmacological effects including skin pigmentation (MC1R), appetite suppression (MC3R/MC4R), pro-sexual activity (MC3R/MC4R), and modulation of exocrine gland function (MC5R) [2][11].

The peptide was designed using molecular dynamics-based conformational analysis. Key structural modifications relative to native alpha-MSH include replacement of methionine-4 with norleucine (preventing oxidative degradation), substitution of L-phenylalanine-7 with D-phenylalanine (enhancing receptor affinity), and cyclization through a lactam bridge between the side chains of aspartic acid and lysine (constraining the peptide in its bioactive conformation and greatly increasing metabolic stability) [1][3]. These modifications rendered MT-II approximately 1000-fold more potent than native alpha-MSH in the classic frog skin bioassay [1][4].

Pharmaceutical development of MT-II was pursued through the 1990s and early 2000s, with Phase I clinical trials demonstrating efficacy in both skin tanning and erectile dysfunction [4][6][7][8]. However, development was ultimately discontinued around 2003 due to the compound's non-selective receptor profile and associated side effects including nausea, blood pressure changes, and concerns about effects on melanocytic nevi [5][11]. Two important derivatives were subsequently developed from the MT-II program: afamelanotide (Melanotan I / Scenesse), a linear alpha-MSH analog approved for erythropoietic protoporphyria, and bremelanotide (PT-141 / Vyleesi), a cyclic metabolite of MT-II approved for hypoactive sexual desire disorder in premenopausal women [11][21].

Despite never receiving regulatory approval for any indication, MT-II is widely sold and self-administered as an unregulated tanning peptide, often obtained from Internet sources of unknown quality [12][16][17].

Molecular Formula

C50H69N15O9

Molecular Weight

1024.2 g/mol

Sequence

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

Structure

Cyclic lactam heptapeptide (lactam bridge between Asp and Lys side chains)

Half-life

~33 min IV; prolonged SC depot effect

Routes Studied

Subcutaneous injection, intranasal

Developer

University of Arizona (Victor Hruby, Mac Hadley)

CAS Number

121062-08-6

Regulatory Status

Not approved for any indication; pharmaceutical development discontinued ~2003

WADA Status

Prohibited (S2 - Peptide Hormones, Growth Factors)

2. Mechanism of Action

Non-Selective Melanocortin Receptor Agonism

Melanotan II binds to and activates four of the five known melanocortin receptors (MC1R, MC3R, MC4R, MC5R), all of which are G protein-coupled receptors (GPCRs) coupled primarily to the stimulatory Gs protein [2][11]. Upon receptor binding, MT-II triggers adenylyl cyclase activation, increasing intracellular cyclic AMP (cAMP) levels. The conserved pharmacophore His-D-Phe-Arg-Trp within the cyclic lactam structure is critical for receptor interaction. MT-II does not significantly activate MC2R (the ACTH receptor), which requires a longer peptide sequence for activation [2][11].

MC1R -- Skin Pigmentation

Activation of MC1R on epidermal melanocytes by MT-II initiates the cAMP-PKA-CREB signaling cascade, leading to upregulation of microphthalmia-associated transcription factor (MITF). MITF drives transcription of melanogenic enzymes (tyrosinase, TRP-1, TRP-2), resulting in increased synthesis of eumelanin -- the brown-black photoprotective pigment [4][10]. This melanogenesis occurs independently of ultraviolet radiation exposure, which is pharmacologically distinct from normal UV-stimulated tanning. The eumelanin produced provides genuine photoprotection by absorbing UV radiation and scavenging free radicals [10].

MC3R and MC4R -- Sexual Function and Appetite

MC3R and MC4R are expressed in hypothalamic and limbic structures including the paraventricular nucleus, medial preoptic area, and nucleus accumbens [7][9]. MT-II activation of MC4R in the hypothalamus stimulates downstream release of oxytocin and dopamine in mesolimbic pathways, which mediate both pro-erectile effects (via spinal cord oxytocinergic neurons projecting to the lumbosacral erection center) and enhanced sexual motivation [7][9][21]. This central mechanism distinguishes melanocortin-based erectogenic agents from PDE5 inhibitors such as sildenafil, which act peripherally on penile vascular smooth muscle.

MC4R activation in the hypothalamus also engages satiety pathways, producing potent anorectic effects. Central or peripheral administration of MT-II dose-dependently suppresses food intake and increases energy expenditure in rodent models [18][19][20]. The melanocortin system is a critical component of the leptin-melanocortin axis regulating energy homeostasis, and genetic disruption of MC4R produces hyperphagia and obesity in both rodents and humans [19].

MC4R -- Cardiovascular Effects

MC4R activation in the central nervous system stimulates sympathetic nervous system outflow, which can acutely elevate blood pressure and heart rate [7][8]. Alpha-MSH and its analogs including MT-II increase mean arterial pressure through this central sympathoexcitatory mechanism. This effect was a key reason that intranasal bremelanotide (PT-141) at higher doses was abandoned for erectile dysfunction [21].

MC5R -- Exocrine Gland Modulation

MC5R is expressed predominantly in peripheral tissues including exocrine glands (sebaceous, lacrimal, preputial). MT-II agonism at MC5R may modulate sebaceous lipid production and exocrine secretory function, though these effects are not well characterized clinically [11].

3. Pharmacokinetics

Absorption

MT-II is administered subcutaneously due to poor oral bioavailability, as the peptide is rapidly degraded by gastrointestinal proteases. Following subcutaneous injection, MT-II is absorbed from the injection depot into systemic circulation with a Tmax of approximately 30-60 minutes [4][5]. The subcutaneous route creates a depot effect that extends the effective duration of drug exposure compared to intravenous administration, as the peptide is gradually released from the injection site into the systemic circulation over several hours. Intranasal administration was also investigated during clinical development and showed bioactivity, though with lower and more variable bioavailability than the subcutaneous route [21].

Distribution

MT-II is a relatively small cyclic peptide (1024.2 Da) with moderate lipophilicity conferred by its cyclic lactam structure and aromatic residues (D-Phe, Trp). The volume of distribution (Vd) has not been precisely determined in human pharmacokinetic studies, but preclinical data suggest distribution into CNS compartments, consistent with its central effects on sexual function, appetite, and sympathetic tone [5][7]. The peptide crosses the blood-brain barrier, as evidenced by its robust central effects (pro-erectile activity, appetite suppression, yawning/stretching complex) following peripheral subcutaneous administration [6][7][9].

Metabolism and Elimination

The elimination half-life of MT-II following intravenous administration is approximately 33 minutes, based on pharmacokinetic data from the Dorr et al. studies [4][5]. Following subcutaneous injection, the apparent half-life is prolonged due to the absorption-rate-limited (flip-flop) kinetics typical of depot formulations, resulting in an effective duration of systemic exposure of several hours. MT-II is metabolized primarily by endopeptidases and aminopeptidases in plasma and tissues. The cyclic lactam structure provides substantial resistance to enzymatic degradation compared to linear alpha-MSH (half-life approximately 3 minutes), which accounts for the roughly 10-fold increase in circulating half-life [1][3]. Renal clearance contributes to elimination of both intact peptide and metabolic fragments. Bremelanotide (PT-141) was identified as a metabolic product of MT-II, formed by C-terminal hydrolysis of the amide to a carboxylic acid [21].

Duration of Biological Effects

Despite the relatively short circulating half-life, the biological effects of MT-II persist for days to weeks. Skin pigmentation effects are cumulative and long-lasting because melanogenesis, once initiated by MC1R activation and MITF upregulation, continues through the multi-day melanin synthesis cycle independently of continued receptor stimulation [4][10]. Melanin deposited in keratinocytes persists until natural epidermal turnover (approximately 28 days). Pro-erectile and appetite-suppressive effects can last 6-12 hours after a single dose, likely due to receptor internalization and sustained intracellular signaling following initial agonist binding. Following repeated dosing, MC1R undergoes desensitization and internalization, which paradoxically contributes to prolonged downstream signaling through sustained intracellular cAMP and MAPK pathway activation within the melanocyte [10]. This receptor internalization/resensitization cycling explains why intermittent dosing (every other day in the Dorr protocol) produces cumulative pigmentation effects over weeks [4].

4. Researched Applications

Skin Pigmentation and Tanning (Moderate Evidence)

The original therapeutic rationale for MT-II was to produce protective skin tanning (eumelanogenesis) without UV exposure, thereby reducing the risk of UV-induced skin cancer [3][4]. The pilot Phase I study by Dorr et al. (1996) demonstrated that subcutaneous MT-II at doses of 0.01-0.03 mg/kg administered every other day for 2 weeks produced visible tanning of the face, upper body, and buttocks in 2 of 3 healthy male volunteers, as measured by quantitative reflectance spectrophotometry [4]. Barnetson et al. (2006) showed in 65 fair-skinned volunteers that a related melanocortin analog increased melanin by 41% in those with the lowest baseline melanin, reduced UV-induced sunburn cells by more than 50%, and decreased thymine dimer formation by 59% in the basal epidermis [10]. These findings provided proof of concept that melanocortin-induced tanning offers genuine photoprotection, though MT-II itself was not pursued further for this indication in favor of the more MC1R-selective afamelanotide.

Erectile Dysfunction in Men (Moderate Evidence)

MT-II demonstrated robust erectogenic activity in multiple controlled clinical trials. Wessells et al. (1998) conducted a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction and found that MT-II (0.025 mg/kg SC) initiated clinically apparent erections in 8 of 10 men, with a mean duration of tip rigidity greater than 80% of 38.0 minutes versus 3.0 minutes with placebo (P=0.0045) [6]. In a subsequent study of 20 men with both psychogenic and organic ED, MT-II produced erections in 17 of 20 subjects without sexual stimulation, and 68% of MT-II doses were associated with increased sexual desire versus 19% of placebo (P<0.01) [7]. A third study in men with organic ED risk factors confirmed efficacy, with 45.3 minutes of tip rigidity greater than 80% versus 1.9 minutes with placebo (P=0.047) [8]. The erectile effects of MT-II were particularly notable because they occurred centrally (via the brain), meaning the drug could work in men for whom PDE5 inhibitors had failed [9][21].

Sexual Dysfunction in Women (Preliminary Evidence)

Diamond et al. (2004) reported that MT-II enhanced sexual function in female subjects, increasing measures of sexual desire and genital arousal [9]. This discovery was made incidentally during studies of the tanning effect and led directly to the development of bremelanotide (PT-141), which was eventually approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women [9][21].

Appetite Suppression and Body Composition (Preclinical Evidence)

Extensive preclinical research has demonstrated that MT-II is a potent appetite suppressant and fat-reducing agent via MC3R/MC4R activation. Central and peripheral MT-II administration dose-dependently reduces food intake in rodent models [19][20]. Chronic MT-II treatment in diet-induced obese mice reduced body mass by 10-15% with persistent reductions in adiposity even after food intake normalized, and abdominal fat pads were approximately 40% smaller than in controls [19]. MT-II reduced both visceral and subcutaneous fat compartments, increased fat catabolism in muscle, and improved glucose and cholesterol metabolism in obese rodents [18][20]. Importantly, calorie-matched control animals did not lose equivalent weight, indicating that MT-II increases energy expenditure independently of appetite suppression [19]. No human clinical trials for obesity have been conducted with MT-II, though the selective MC4R agonist setmelanotide (Imcivree) was subsequently approved for rare genetic obesity disorders.

Photoprotection Research (Moderate Evidence)

Research into melanocortin-induced photoprotection demonstrated that MT-II and related analogs increase eumelanin content, enhance DNA repair mechanisms, and reduce UV-induced DNA damage [10]. The Barnetson et al. (2006) study provided the strongest evidence, showing that melanocortin-stimulated tanning in fair-skinned individuals produced measurable reductions in UV photodamage markers [10]. However, the photoprotection indication was pursued clinically with afamelanotide rather than MT-II, due to afamelanotide's more favorable receptor selectivity profile.

Lipodystrophy and Metabolic Effects (Preclinical Evidence)

MT-II has been shown in animal models to reduce adipose tissue through multiple mechanisms beyond caloric restriction, including enhanced lipid oxidation and thermogenesis [18][19][20]. Choi et al. (2007) demonstrated that MT-II produced a general reduction in both visceral and subcutaneous adipose tissue in diet-induced obese mice [20]. These metabolic effects are mediated primarily through MC4R activation in the hypothalamus and may involve enhanced sympathetic innervation of adipose tissue. Clinical translation of these findings has not been attempted with MT-II.

5. Dose-Response Relationships

Pigmentation Dose-Response

In the Dorr et al. (1996) Phase I study, subcutaneous MT-II was administered at escalating doses of 0.01, 0.015, 0.02, and 0.025 mg/kg [4]. Measurable increases in skin reflectance (indicating increased melanin content) were dose-dependent, with the 0.02-0.03 mg/kg range producing clinically visible tanning after 5 doses over 2 weeks [4]. At 0.01 mg/kg, minimal pigmentation changes were observed, establishing this as the approximate threshold dose for tanning effects. Higher doses (0.025 mg/kg and above) produced more rapid and intense pigmentation but were associated with dose-limiting nausea in a significant proportion of subjects [4]. The pigmentation response exhibits a cumulative dose-response pattern rather than a single-dose threshold, meaning repeated administration at subthreshold single doses can produce significant tanning over time. Pigmentation was most pronounced on the face, upper trunk, and buttocks -- areas with the highest melanocyte density [4].

Erectile Response Dose-Response

For erectile function, a single subcutaneous dose of 0.025 mg/kg (approximately 1.75-2.0 mg in an average adult male) was the dose used across the three Wessells et al. clinical trials [6][7][8]. This dose produced clinically significant erections (tip rigidity greater than 80%) in 80-85% of subjects within 30-90 minutes of injection. The erectile response appeared to have a steeper dose-response curve than pigmentation, with robust effects at 0.025 mg/kg [6]. Doses below 0.02 mg/kg were generally insufficient for reliable erectile effects. The onset of erectile effects was preceded by the characteristic yawning/stretching complex, which appeared at similar doses and served as a clinical indicator of central melanocortin activation [6][7].

Appetite Suppression Threshold

In preclinical studies, the anorectic dose-response of MT-II was evaluated primarily via central (intracerebroventricular) administration, where doses of 0.5-5 nmol produced dose-dependent suppression of food intake in rodents [19][20]. With peripheral (subcutaneous or intraperitoneal) administration, higher doses were required due to blood-brain barrier transit, with 1-10 mg/kg ranges used in rodent models [18][19][20]. The appetite-suppressive effect appears to have a lower threshold than the nausea-producing effect in animal models, though this distinction is less clear in humans where nausea itself confounds appetite assessment [4].

Underground "Loading Phase" Protocol

In unregulated use, a common protocol involves an initial "loading phase" of daily subcutaneous injections of 0.5-1.0 mg (not weight-based) for 7-14 days, followed by a "maintenance phase" of 0.5-1.0 mg once or twice weekly to sustain pigmentation [12][16]. These doses are not derived from clinical trial data and carry significant risks. The loading phase concept exploits the cumulative melanogenic response, with users titrating based on visible tanning and tolerance to nausea. Some users co-administer antihistamines or anti-emetics to manage nausea. This self-dosing approach is inherently hazardous given the product quality variability documented by Breindahl et al. (2015), where actual peptide content ranged from 43-88% of the labeled amount [17].

6. Comparative Effectiveness

MT-II vs Afamelanotide (Scenesse)

Afamelanotide (Melanotan I, NDP-alpha-MSH) is a linear 13-amino-acid alpha-MSH analog that is more MC1R-selective than MT-II [10][11]. While MT-II activates MC1R, MC3R, MC4R, and MC5R with comparable potency, afamelanotide has preferential activity at MC1R with relatively less activation of MC3R/MC4R, resulting in potent melanogenic effects without the pronounced sexual, appetite, and cardiovascular side effects of MT-II [10][11]. Afamelanotide was approved by the EMA (2014) and FDA (2019) as a 16 mg subcutaneous implant (Scenesse) for erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. The implant formulation provides sustained release over approximately 60 days, avoiding the peak-trough dynamics and repeated injections required with MT-II. In EPP clinical trials, afamelanotide increased pain-free time in sunlight and melanin density without the nausea, erectile effects, or cardiovascular changes characteristic of MT-II [10]. For pure tanning/photoprotection applications, afamelanotide represents the pharmacologically optimized successor to MT-II.

MT-II vs PT-141/Bremelanotide (Vyleesi)

Bremelanotide (PT-141) is a cyclic heptapeptide metabolite of MT-II, differing only by a C-terminal free acid (-OH) instead of the amide (-NH2) [21]. Despite this minimal structural difference, bremelanotide has a relatively more favorable profile for sexual function applications. It retains MC3R/MC4R agonism responsible for pro-sexual effects while producing somewhat less melanogenic activity than MT-II [9][21]. Bremelanotide was approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg fixed-dose subcutaneous autoinjector used on-demand (at least 45 minutes before anticipated sexual activity). In Phase III trials (RECONNECT), bremelanotide significantly increased sexual desire and reduced distress compared to placebo. Notably, the intranasal formulation of bremelanotide for male ED was abandoned after Phase II/III trials revealed dose-dependent blood pressure elevations, a side effect inherited from the parent MT-II molecule and mediated by MC4R [21]. The subcutaneous route at lower doses mitigated this concern sufficiently for the HSDD indication.

MT-II vs Setmelanotide (Imcivree)

Setmelanotide is a highly selective MC4R agonist approved by the FDA (2020) for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency [19]. Unlike MT-II, which activates all four melanocortin receptors non-selectively, setmelanotide was designed to target MC4R specifically, maximizing appetite-suppressive and metabolic effects while minimizing MC1R-mediated pigmentation and other off-target activities. In clinical trials for genetic obesity, setmelanotide produced 25-40% reductions in body weight with sustained hypophagia. While setmelanotide does cause some skin darkening (MC4R and MC1R are structurally related, and complete selectivity is difficult), the degree of pigmentation is substantially less than with MT-II. Setmelanotide represents the targeted therapeutic realization of the appetite-suppressive pathway first characterized with MT-II in preclinical studies [19][20].

Why MT-II Was Abandoned in Favor of Selective Analogs

MT-II's non-selective melanocortin receptor profile was ultimately its principal liability as a pharmaceutical candidate. Activation of MC1R, MC3R, MC4R, and MC5R simultaneously produced a complex pharmacological profile where therapeutic effects (tanning, pro-sexual activity, appetite suppression) were inextricable from adverse effects (nausea, blood pressure elevation, spontaneous erections, melanocytic proliferation) [5][11]. The strategy of developing receptor-selective analogs allowed each therapeutic indication to be pursued independently with improved safety margins. Afamelanotide captured the MC1R tanning/photoprotection application, bremelanotide captured the MC3R/MC4R sexual function application, and setmelanotide captured the MC4R appetite/obesity application [11][21]. This receptor-selective development strategy is a textbook example of rational drug design from a promiscuous lead compound.

7. Clinical Evidence Summary

The clinical evidence base for MT-II consists primarily of small Phase I studies for skin pigmentation and controlled crossover trials for erectile dysfunction. While these trials demonstrated clear biological activity, they enrolled limited numbers of subjects and were not powered for comprehensive safety evaluation. No Phase III pivotal trials were conducted with MT-II. The compound's clinical development program was effectively replaced by two derivative compounds with more favorable profiles: afamelanotide for dermatological applications and bremelanotide for sexual dysfunction.

8. Dosing in Research

The following table summarizes doses used in published clinical studies. MT-II has never been approved for therapeutic use, and no standardized dosing regimen has been established.

In the Dorr et al. (1996) Phase I study, doses were escalated from 0.01 mg/kg to 0.03 mg/kg subcutaneously every other day. Tanning effects were observed at cumulative exposure of 5 doses over 2 weeks. Nausea became dose-limiting above 0.025 mg/kg [4]. In erectile dysfunction studies, a single subcutaneous dose of 0.025 mg/kg was used, corresponding to approximately 1.75-2.0 mg for an average adult male [6][7][8]. For reference, the approved dose of the derivative bremelanotide (Vyleesi) is 1.75 mg fixed-dose subcutaneous injection [21].

9. Safety and Side Effects

Common Adverse Effects

Nausea is the most frequently reported adverse effect in clinical trials and the primary dose-limiting toxicity. In the Dorr et al. (1996) study, mild nausea occurred at most dose levels, while at 0.025 mg/kg, 12.9% of subjects experienced severe nausea [4]. In the Wessells et al. (2000) organic ED study, 4 of 19 MT-II injections were associated with severe nausea [8].

Facial flushing was commonly reported and typically transient, occurring within the first hour after injection [4][7].

Yawning and stretching -- a stereotypical "stretching and yawning complex" was consistently observed in clinical trials, appearing to correlate with the onset of pro-erectile effects. This is believed to be centrally mediated through oxytocinergic pathways [4][6][7].

Spontaneous erections -- penile erections occurring without sexual stimulation were reported as both a therapeutic effect and an adverse effect, typically lasting 1-5 hours post-injection depending on dose [4][6].

Cardiovascular Effects

MT-II and related melanocortin agonists produce transient increases in blood pressure and heart rate through central sympathoexcitatory mechanisms mediated by MC4R activation in the hypothalamus, which increases sympathetic nervous system outflow [7][8]. In clinical trials, systolic blood pressure increases of 10-25 mmHg and heart rate increases of 5-15 bpm were documented following subcutaneous doses of 0.025 mg/kg [7][8]. In one published case, a previously normotensive patient presented with blood pressure of 165/95 mmHg following MT-II use. In the bremelanotide (PT-141) development program, intranasal doses of 10-20 mg produced dose-dependent blood pressure elevations that led to abandonment of that formulation for male erectile dysfunction [21]. While the subcutaneous route and lower doses used in the approved bremelanotide product (Vyleesi, 1.75 mg) mitigated this effect, the cardiovascular risk remains clinically relevant for MT-II, which activates MC4R at full potency. Concurrent use with sympathomimetics, MAO inhibitors, or in patients with pre-existing hypertension, coronary artery disease, or arrhythmias carries additional risk. The blood pressure elevation is typically transient (resolving within 2-4 hours) but can be clinically significant in vulnerable populations.

Melanocytic Changes and Melanoma Risk

The relationship between MT-II and melanocytic neoplasia is the most debated and clinically significant safety concern. The evidence consists of case reports, case series, and biological plausibility analysis.

Eruptive and changing nevi -- incidence and characterization:

• Cousen et al. (2009) reported sudden eruption of more than 100 new melanocytic nevi, many clinically and dermatoscopically atypical, within weeks of a 4-week MT-II course. Histopathology revealed dysplastic nevi with some showing severe dysplasia [13].
• Langan et al. (2009) reported the first cases of transformation of pre-existing moles, including a severely dysplastic melanocytic nevus, in two women (ages 30 and 48, Fitzpatrick skin types I and II) using melanotan [14].
• In the Reid & Fitzgerald (2015) systematic review of 18 clinical trials and 21 case presentations, darkening of existing nevi was one of the most commonly reported adverse effects, occurring in a substantial proportion of users, though precise incidence rates were not calculable from the heterogeneous data sources [16].
• In the original Dorr et al. clinical studies, new nevi development was observed in subjects receiving MT-II, with investigators noting the appearance of new pigmented lesions during the treatment period [4].

Melanoma risk assessment -- case reports vs epidemiological data:

• Hjuler et al. (2014) reported melanoma emerging during or shortly after MT-II use in a previously low-risk individual [15]. At least 5 additional case reports in the literature have described melanoma or melanoma in situ in MT-II users, though the total number is likely underreported given the unregulated nature of use.
• A 2025 case report described a 22-year-old female who developed oral mucosal malignant melanoma in the anterior maxilla after using Melanotan II nasal spray for tanning purposes [22]. Histological analysis confirmed malignant melanoma, and the patient required surgical resection followed by immunotherapy. Risk factor analysis concluded that the most likely cause was the Melanotan II nasal spray, as oral pigmentation began shortly after its initiation. This is notable as the first published case linking MT-II nasal spray (rather than subcutaneous injection) to melanoma development.
• No epidemiological cohort or case-control studies have been conducted to quantify the melanoma risk associated with MT-II, meaning the absolute risk increase (if any) remains unknown.
• Causality is confounded by several factors: MT-II users frequently co-use tanning beds (an established melanoma risk factor with relative risk of 1.6-3.0 for indoor tanning), the background incidence of melanoma in fair-skinned populations is approximately 20-30 per 100,000 per year, and reporting bias means that melanomas in MT-II users are more likely to be published as case reports [16].
• The biological plausibility is strong. MC1R activation drives melanocyte proliferation through the cAMP-MITF axis, and loss-of-function MC1R variants (which impair this signaling) are established melanoma risk alleles. Pharmacological hyperactivation of MC1R could theoretically promote clonal expansion of pre-malignant melanocytes. However, the counter-argument exists that eumelanin production (enhanced by MC1R activation) is photoprotective and that MC1R signaling promotes DNA repair in melanocytes, which could be anti-tumorigenic [10].
• The net melanoma risk of MT-II likely depends on whether it is used with or without concurrent UV exposure. MT-II combined with tanning bed use may represent a synergistically elevated risk profile.

Rare and Serious Adverse Events

Published case reports have documented several serious adverse events following MT-II self-administration:

• Renal infarction: Brouwer et al. (2020) reported a case of acute renal infarction in a young, otherwise healthy individual following MT-II injection, presenting with sudden-onset flank pain, elevated LDH, and characteristic wedge-shaped perfusion defects on CT angiography [23]. Additional case reports have documented similar events [16]. The proposed mechanism involves MC4R-mediated sympathetic activation causing vasospasm or a pro-thrombotic state, potentially compounded by dehydration or concurrent stimulant use. Renal infarction is a potentially life-threatening emergency requiring urgent anticoagulation.
• Rhabdomyolysis: Nelson et al. (2012) reported a case of rhabdomyolysis (elevated creatine kinase greater than 10 times the upper limit of normal, myoglobinuria, and renal impairment) following MT-II use [24]. The mechanism may involve sustained smooth muscle contraction or direct myotoxic effects of product impurities.
• Systemic toxidrome: The Reid & Fitzgerald (2015) review documented cases of systemic toxicity presenting with severe nausea, vomiting, hypertension, tachycardia, and altered mental status -- consistent with a melanocortin-mediated sympathomimetic crisis [16].
• Comprehensive safety review: van der Bent et al. (2017) published a systematic safety assessment of melanotan-II, documenting the full spectrum of adverse events including nausea, cardiovascular effects, melanocytic changes, and the serious events described above [25]. This review concluded that the safety profile of MT-II remains inadequately characterized and that unregulated use poses significant health risks.

These events are likely associated with unregulated product use where dose accuracy and purity cannot be assured, and where users may inadvertently administer doses far exceeding those studied in clinical trials [17].

Product Quality Concerns

The unregulated nature of MT-II distribution represents a fundamental safety hazard independent of the peptide's inherent pharmacology. Breindahl et al. (2015) conducted LC-UV-MS/MS analysis of illegally sold MT-II products purchased online and found that actual peptide content ranged from 4.32 to 8.84 mg per vial versus a claimed 10 mg (43-88% of labeled content) [17]. Up to 6% of product content consisted of unknown impurities, including oxidized peptide variants, truncated sequences, and unidentified compounds whose pharmacological and toxicological profiles are entirely unknown [17]. Additional concerns include lack of sterility assurance in products intended for injection (risking bacterial contamination and injection-site infections), absence of endotoxin testing, potential for cross-contamination with other peptides during non-GMP manufacture, and degradation from improper storage and shipping. Users who reconstitute lyophilized MT-II with bacteriostatic water and self-inject face risks of infection, dosing errors, and exposure to degradation products. The combination of variable peptide content with non-weight-based dosing by unregulated users creates a particularly dangerous scenario where effective doses may vary 2-fold or more between product lots [17].

Regulatory Warnings

Health authorities in the United Kingdom, Australia, Ireland, the United States, and other countries have issued repeated warnings against MT-II use. The compound is not approved for any therapeutic or cosmetic indication in any jurisdiction. Starting in 2007, agencies began issuing formal advisories highlighting the risks of self-injection with unregulated melanotan products [12][16].

10. Related Peptides

See also: Afamelanotide (Scenesse / Melanotan I), PT-141 (Bremelanotide / Vyleesi), Alpha-MSH (Alpha-Melanocyte Stimulating Hormone)

Melanotan II occupies a central position in the melanocortin peptide family and has given rise to two approved pharmaceutical products:

• Afamelanotide (Scenesse / Melanotan I): A linear 13-amino-acid analog of alpha-MSH (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2). Developed at the University of Arizona alongside MT-II, it is more MC1R-selective and was approved by the EMA (2014) and FDA (2019) as a 16 mg subcutaneous implant for the prevention of phototoxicity in erythropoietic protoporphyria.

• PT-141 / Bremelanotide (Vyleesi): A cyclic heptapeptide metabolite of MT-II that differs by having a hydroxyl group where MT-II has an amide (C-terminal -OH vs -NH2). Developed by Palatin Technologies after they ceased MT-II development in 2000, bremelanotide was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. Its pro-sexual effects are primarily mediated through MC4R.

• Alpha-MSH: The endogenous 13-amino-acid melanocortin peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) from which both MT-I and MT-II were derived. Alpha-MSH is far less potent than MT-II and has a very short half-life of approximately 3 minutes due to rapid enzymatic degradation.

• Setmelanotide (Imcivree): A selective MC4R agonist approved by the FDA for rare genetic obesity disorders caused by POMC, PCSK1, or LEPR deficiency. Structurally distinct from MT-II but targets the same MC4R appetite regulation pathway.

11. References

1. [1] Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ (1989). Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. DOI PubMed
2. [2] Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD (1995). Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-MSH-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. DOI PubMed
3. [3] Lan J, Cho CS, Hruby VJ (1994). Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. DOI PubMed
4. [4] Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. DOI PubMed
5. [5] Hadley ME, Dorr RT (1998). Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol. PubMed
6. [6] Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. DOI PubMed
7. [7] Wessells H, Levine N, Hadley ME, Dorr R, Hruby V (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. DOI PubMed
8. [8] Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. DOI PubMed
9. [9] Diamond LE, Earle DC, Rosen RC, Wilber MS, Molinoff PB (2004). Discovery that a melanocortin regulates sexual functions in male and female humans. Ann N Y Acad Sci. DOI PubMed
10. [10] Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, Humphrey SM, Kleinig MJ (2006). [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. DOI PubMed
11. [11] Hruby VJ, Cai M, Grieco P, Han G, Kavarana M, Trivedi D (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. DOI PubMed
12. [12] Langan EA, Nie Z, Rhodes LE (2010). Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?. Br J Dermatol. DOI PubMed
13. [13] Cousen P, Sherrington C, Halliday GM (2009). Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. DOI PubMed
14. [14] Langan EA, Ramlogan D, Jamieson LA, Rhodes LE (2009). Change in moles linked to use of unlicensed 'sun tan jab'. BMJ. DOI PubMed
15. [15] Hjuler KF, Lorentzen HF (2014). Melanoma associated with the use of melanotan-II. Dermatology. DOI PubMed
16. [16] Reid CK, Fitzgerald T (2015). An unhealthy glow? A review of melanotan use and associated clinical outcomes. Perform Enhanc Health. DOI
17. [17] Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Sheridan J, Sherlock K, Binnington J (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. DOI PubMed
18. [18] Pieters R, Vajro P (2003). MTII administered peripherally reduces fat without invoking apoptosis in rats. Obes Res. PubMed
19. [19] Irani BG, Xiang Z, Yarandi HN, Holder JR, Moore MC, Bauber RE, Gilber Z, Haskell-Luevano C (2017). Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction. Am J Physiol Endocrinol Metab. DOI PubMed
20. [20] Choi DL, Davis JF, Magrisso IJ, Fitzgerald ME, Lipton JW, Benoit SC (2007). The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. Peptides. DOI PubMed
21. [21] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. DOI PubMed
22. [22] Various (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. Int J Oral Maxillofac Surg. PubMed
23. [23] Brouwer AH, et al. (2020). Renal infarction after melanotan II use. Clinical Kidney Journal.
24. [24] Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology.
25. [25] van der Bent SAS, Wolkerstorfer A, Rustemeyer T (2017). The use of melanotan and tanning injections: a systematic review of reported adverse effects. Journal of the European Academy of Dermatology and Venereology.